Medico Intercontinental Ltd
Medico Intercontinental Ltd Formerly Known as M/S. Intercontinental Leasing & Finance Company Limited) was incorporated in 1984. Currently, they are providing a platform to all research based biopharmaceutical companies reaching their Novel and innovative therapies. The Company is into the business of trading various medicines. [1] [2]
- Market Cap ₹ 54.0 Cr.
- Current Price ₹ 54.0
- High / Low ₹ 122 / 39.0
- Stock P/E 22.1
- Book Value ₹ 37.6
- Dividend Yield 0.00 %
- ROCE 7.71 %
- ROE 5.40 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Company has a low return on equity of 7.77% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.02 | 0.27 | 0.23 | 2.03 | 0.00 | 9.95 | 46.93 | 41.02 | 39.25 | 48.88 | 44.04 | 57.79 | |
0.00 | 0.00 | 0.27 | 0.32 | 1.97 | 0.34 | 9.27 | 44.73 | 38.68 | 36.98 | 46.38 | 41.44 | 53.98 | |
Operating Profit | 0.00 | 0.02 | 0.00 | -0.09 | 0.06 | -0.34 | 0.68 | 2.20 | 2.34 | 2.27 | 2.50 | 2.60 | 3.81 |
OPM % | 100.00% | 0.00% | -39.13% | 2.96% | 6.83% | 4.69% | 5.70% | 5.78% | 5.11% | 5.90% | 6.59% | ||
0.00 | 0.00 | 0.00 | 0.00 | -0.05 | 0.39 | 0.36 | 0.02 | 0.16 | 0.18 | 0.34 | 0.42 | 0.32 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.66 | 0.78 | 0.52 | 0.37 | 0.22 | 0.43 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.06 | 0.10 | 0.09 | 0.18 | 0.28 |
Profit before tax | 0.00 | 0.02 | 0.00 | -0.09 | 0.01 | 0.05 | 1.03 | 1.54 | 1.66 | 1.83 | 2.38 | 2.62 | 3.42 |
Tax % | 50.00% | -33.33% | 0.00% | 40.00% | 26.21% | 27.27% | 27.71% | 28.42% | 28.15% | 27.48% | |||
0.00 | 0.01 | 0.00 | -0.06 | 0.01 | 0.03 | 0.76 | 1.12 | 1.20 | 1.31 | 1.70 | 1.90 | 2.44 | |
EPS in Rs | 0.00 | 0.40 | 0.00 | -0.18 | 0.03 | 0.09 | 2.34 | 3.45 | 3.69 | 4.03 | 1.70 | 1.90 | 2.44 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5.88% | 5.26% |
Compounded Sales Growth | |
---|---|
10 Years: | 116% |
5 Years: | 35% |
3 Years: | 2% |
TTM: | -6% |
Compounded Profit Growth | |
---|---|
10 Years: | 69% |
5 Years: | 20% |
3 Years: | 17% |
TTM: | 27% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 11% |
1 Year: | -39% |
Return on Equity | |
---|---|
10 Years: | 9% |
5 Years: | 10% |
3 Years: | 8% |
Last Year: | 5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.25 | 0.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 10.00 | 10.00 | 10.00 |
Reserves | 0.02 | 0.04 | 0.04 | -0.02 | -0.01 | 0.02 | 0.78 | 1.90 | 3.09 | 4.40 | 24.30 | 26.10 | 27.58 |
0.02 | 0.02 | 0.02 | 0.23 | 0.02 | 0.02 | 0.09 | 8.56 | 4.81 | 6.21 | 2.27 | 0.96 | 7.82 | |
0.01 | 0.01 | 0.02 | 0.07 | 0.93 | 0.62 | 5.00 | 5.46 | 5.27 | 3.85 | 7.81 | 2.39 | 3.32 | |
Total Liabilities | 0.30 | 0.32 | 3.33 | 3.53 | 4.19 | 3.91 | 9.12 | 19.17 | 16.42 | 17.71 | 44.38 | 39.45 | 48.72 |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.12 | 0.24 | 0.20 | 0.48 | 0.33 | 2.03 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 3.57 | 4.35 | 4.20 | 4.20 | 4.20 | 5.82 |
0.30 | 0.32 | 3.33 | 3.53 | 4.18 | 3.90 | 9.09 | 15.48 | 11.83 | 13.31 | 39.70 | 34.92 | 40.87 | |
Total Assets | 0.30 | 0.32 | 3.33 | 3.53 | 4.19 | 3.91 | 9.12 | 19.17 | 16.42 | 17.71 | 44.38 | 39.45 | 48.72 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | -2.96 | 0.12 | -0.04 | 0.02 | 0.95 | -6.55 | 5.44 | 1.10 | -11.95 | 5.73 | ||
0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.03 | -3.68 | -0.94 | -0.80 | -5.02 | -6.65 | ||
0.00 | 3.00 | 0.00 | 0.00 | 0.00 | 0.07 | 9.22 | -4.51 | 0.87 | 20.63 | -1.63 | ||
Net Cash Flow | 0.00 | 0.04 | 0.12 | -0.05 | 0.02 | 0.99 | -1.01 | -0.02 | 1.17 | 3.66 | -2.54 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 0.00 | 0.00 | 79.35 | 339.83 | 237.34 | 98.54 | 71.45 | 78.86 | 186.08 | 123.74 | ||
Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 25.84 | 22.28 | 36.32 | 26.47 | 31.98 | 45.60 | ||
Days Payable | 200.54 | 45.26 | 51.21 | 39.76 | 64.82 | 19.26 | ||||||
Cash Conversion Cycle | 0.00 | 0.00 | 79.35 | 339.83 | 62.63 | 75.57 | 56.56 | 65.57 | 153.24 | 150.08 | ||
Working Capital Days | 4,927.50 | 4,380.00 | 5,125.87 | 345.22 | 78.50 | 76.45 | 57.13 | 66.86 | 157.11 | 143.30 | ||
ROCE % | 0.00% | 6.67% | 0.00% | -2.66% | 1.79% | 1.53% | 28.07% | 24.68% | 19.63% | 18.79% | 10.91% | 7.71% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Newspaper Publication of unaudited financial results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2024.
-
Results - Financials Results For The Quarter And Half Year Ended 30Th September, 2024.
14 Nov - Board approved unaudited financial results for Q2 2024.
-
Board Meeting Outcome for Compliances Of Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
14 Nov - Board approved unaudited financial results for Q2 2024.
-
Board Meeting Intimation for Board Meeting In Compliance Of Regulation 29, 30 And 33 Of The SEBI (LODR) Regulations, 2015.
6 Nov - Board meeting scheduled to approve financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
3 Oct - Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30.09.2024.
About[1]
Medico is engaged in trading of Pharmaceutical products. In past few years, their core portfolio has been textile products. Current management brings expertise in the pharma industry and so the company has diversified to a pharma company.